Enlivex Therapeutics (NASDAQ:ENLV) Trading Down 3% – Time to Sell?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s share price fell 3% on Tuesday . The company traded as low as $0.6810 and last traded at $0.6926. 355,538 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 402,283 shares. The stock had previously closed at $0.7142.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ENLV. HC Wainwright raised their price target on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.50.

Enlivex Therapeutics Price Performance

The stock has a market capitalization of $164.41 million, a P/E ratio of -1.26 and a beta of 1.47. The business’s 50 day simple moving average is $0.82 and its 200-day simple moving average is $0.94.

Hedge Funds Weigh In On Enlivex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in Enlivex Therapeutics in the fourth quarter valued at approximately $33,000. Susquehanna International Group LLP bought a new position in shares of Enlivex Therapeutics during the third quarter worth $57,000. Invesco Ltd. bought a new position in shares of Enlivex Therapeutics during the fourth quarter worth $43,000. XTX Topco Ltd boosted its position in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after purchasing an additional 19,132 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Enlivex Therapeutics by 244.1% during the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after purchasing an additional 52,553 shares in the last quarter. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.